Current EU Research Funding Opportunities

Here you can find the EU calls that are most relevant for UKE.
For further information and advice, contact us .

Co-financed European Partnerships in the area of health

Part of the Horizon Europe Cluster Health budget is allocated towards co-funded partnerships, networks made up of national/regional funding agencies, research institutions and further stakeholders. These networks work closely with the European Commission (EC) and often publish transnational calls on an annual basis allowing for projects to be funded by the EC and the national/regional funding bodies. Announcements of these calls normally take place towards the end of the calendar year.

We have summarised the partnerships in the area of health. If you see a partnership that is relevant to your field, we recommend that you subscribe to their communication channels to stay up to date on their developments.

  • Pandemic Preparedness (BE READY Now) Partnership

    BE READY (Building a European strategic Research and innovation Area in Direct Synergy with EU and international initiatives for pandemic preparedness) is a project funded under Horizon Europe designed to improve the EU’s preparedness to predict and respond to emerging infectious health threats.


  • European Partnership on Personalised Medicine (EP PerMed)

    EP PERMed is a coordination platform that brings together European as well as international, national and regional ministries and funding organisations, agencies and authorities, joining forces on several levels and sectors.

    Joint translational calls are expected to be published at the end of the year. Stay posted for opportunities: Calls - European Partnership for Personalised Medicine - EP PerMed

  • European Partnership on Chemical Risk Assessment (PARC)

    PARC aims to develop next-generation chemical risk assessment to protect human health and the environment. It supports the European Union's Chemicals Strategy for Sustainability and the European Green Deal's “Zero pollution” ambition with new data, knowledge, methods and tools, expertise and networks.

    Stay posted for funding opportunities: Opportunities | Parc

  • European Rare Disease Alliance (ERDERA)

    The aim of the European Rare Disease Research Alliance (ERDERA) is to advance research in rare disease prevention, diagnosis and treatment and to build on the results of other EU-funded projects such as the European Joint Programme on Rare Diseases . The alliance will provide a number of funding opportunities.

    O p e n:

    Networking Support Scheme

    The Networking Support Scheme (NSS ) aims to promote transnational networking events to share knowledge across borders, disciplines and sectors and to cover topics related to rare diseases and rare cancers.

    Events can be funded to an amount of EUR 30.000 and must:

    • Include at least three different eligible countries
    • Involve early stage researcher and patient advocacy
    • Promote the inclusion of typically underrepresented countries (UCs)

    The call is permanently open with scheduled collection rounds in October and April of each year (until 2029).

    ERDERA Clinical Trial Call 2026


    The ERDERA Clinical Trial Call (ECTC) supports multinational, GCP‑compliant Phase I, Phase I/II and Phase II interventional clinical trials in rare diseases.

    Main points:

    • Priority areas: paediatric rare diseases; rapidly progressive rare diseases; and rare diseases with no approved therapeutic options or with substantial residual unmet medical need despite existing treatments
    • Eligible interventions: small molecules (including repurposed drugs), ATMPs (with GMP‑validated manufacturing appropriate for Phase I/II), biologics/new biological entities, and repurposed biologics
    • Consortium requirements: at least three independent partners from at least three different eligible ERDERA countries. Each consortium must include a designated Clinical Trial Sponsor, a Coordinating Investigator, and at least one funded patient partner. Access to a qualified multinational Clinical Trial Management Organisation (CTMO) must be secured
    • Funding: €1 million to €5 million per project
    • Timeline: Expression of Interest (EOI) 10 September 2026 | Short Proposal 29 October 2026

    For further information, contact us .


  • ERA4HEALTH: Partnership Fostering a European Research Area for Health

    The Partnership “Fostering a European Research Area for Health” (ERA4Health) aims at establishing a flexible and effective coordination between funding organisations in the European Research Area (ERA) in priority areas addressing European Public Health Needs.

    F o r t h c o m i n g:

    The European Partnership ERA4Health has pre-announced its 9th joint transnational call, “ IICS4all 2027 - Multinational Investigator-Initiated Clinical Studies in Cardiovascular, Autoimmune, Metabolic and Non-Communicable Respiratory Diseases, including Underrepresented Populations”, expected to be launched on 27 October 2026.

    The aim of the call is to support pragmatic, phase III, randomised controlled, multi-national interventional Investigator-Initiated Clinical Studies:

    • Study types: Comparative-effectiveness studies and drug repurposing studies of off-patent drugs
    • Eligible disease areas: Cardiovascular diseases, metabolic disorders, autoimmune diseases and non-communicable respiratory diseases. Studies must ensure inclusivity and diversity in the study population.
    • Project duration: up to 48 Months
    • Deadline for pre-proposal submission: 14 January 2027

    An online info session for applicants will be held on 10 November 2026.

    For further information, follow the above links and/or contact us .